The pitch deck used to start with a vision for transforming Canadian healthcare. Now, many Vancouver health tech founders are opening with a different proof point: a signed pilot agreement from a U.S. health system.

Across Metro Vancouver's seed-stage digital health cohort—including firms focused on remote patient monitoring, care navigation, and clinical AI—a strategic shift is underway. Founders are increasingly routing around Canada's lengthy hospital procurement processes to secure U.S. pilots first. The goal is not to abandon the domestic market, but to use American validation as a catalyst for a Canadian Series A.

The math is clear. Canadian hospital procurement cycles average 24 to 36 months from RFP to signed contract. Comparable U.S. health system pilots are often closing in six to twelve months. For a seed-stage company managing limited runway, that gap is an existential variable.

Founders within the CDL-Vancouver ecosystem have noted that the Canadian system is built for incumbents rather than innovators. This perspective has become common wisdom, pushing founders toward a counterintuitive conclusion: prove the technology in the U.S., then return home with leverage.

Investors are paying attention. BC's digital health sector attracted approximately $180 million CAD in venture investment in 2024–25, according to BC Tech Association estimates. This capital is increasingly contingent on third-party validation. Industry trends suggest that Series A term sheets are frequently structured around U.S. pilot data as a milestone trigger.

This pattern mirrors the enterprise SaaS boom of five years ago. Founders then faced similar barriers: slow domestic procurement and relationship-gated access. Those who succeeded landed U.S. logos first, then returned to Canadian institutional capital with a compelling growth narrative. Several of those companies subsequently raised $30 million to $80 million CAD Series B rounds while maintaining their base in Vancouver.

Health tech is tracing a similar arc, with higher stakes. The remote patient monitoring market is projected to reach USD $175 billion globally by 2030, yet Canadian firms currently hold less than three per cent of that market. The U.S. pilot pathway is not merely a fundraising tactic; it is a critical window for market entry.

The mechanism is straightforward: a Vancouver founder identifies a U.S. regional health system—often a mid-sized operator where procurement is more agile—and structures a paid or partially paid pilot with defined outcome metrics. If the data holds, the founder returns to Vancouver with a referenceable U.S. customer and a credible path to contract expansion. That package holds significantly more value to a Series A investor than a letter of intent from a Canadian health authority.

Genome BC's commercialization programs and NRC-IRAP's health tech funding stream have been instrumental in supporting the early-stage infrastructure that makes these pilots possible. By providing non-dilutive capital, these programs help founders survive long enough to close U.S. agreements. Genome BC's commercialization support and NRC-IRAP health tech recipients in BC represent a vital layer of the capital stack.

However, the strategy carries risks. U.S. pilots can stall if an internal champion leaves the health system. Furthermore, HIPAA compliance and data residency requirements add legal complexity. There is also the question of whether U.S. clinical outcomes data translates seamlessly to Canadian health system contexts—a concern raised by some domestic procurement officers.

Founders running this play are aware of these trade-offs. They are making a deliberate bet that the speed and validation of a U.S. pilot outweigh the friction, and that returning to Canadian procurement with a proven product and U.S. reference customers fundamentally shifts the negotiating dynamic.

Vancouver possesses the clinical research infrastructure—including UBC, the BC Children's Hospital Research Institute, and the PHSA—to produce world-class health tech. The missing link has been a fast feedback loop between product and market. The U.S. pilot pathway is filling that gap.

If the SaaS parallel holds, the next 18 months will see a cluster of Vancouver health tech companies return from U.S. pilots with the data required to raise $10 million to $20 million CAD Series A rounds. The founders who identified this signal early will have a significant head start.